A Phase 2 interventional study of LY4100511 and Placebo in Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 58 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 13th largest by enrollment, is one of 2 that started in 2024, is one of 9 in phase 2, and was the 34th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, one of the names counted as Eli Lilly and Company. Under that name alone:
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LY4100511 200 milligrams (mg) administered orally twice daily (BID) for 12 weeks.
Drug: LY4100511
Participants received LY4100511 400 mg administered orally BID for 12 weeks.
Drug: LY4100511
Participants received LY4100511 800 mg administered orally once daily (QD) for 12 weeks, with matching placebo administered in the evening.
Drug: LY4100511
Participants received placebo administered orally BID for 12 weeks.
Drug: Placebo
Administered orally
Administered orally
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg)
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 12
Percentage of participants achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 12. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): * 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur * 1 = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling * 2 = Mild: Pink to light red color; slight thickening; mainly fine scaling * 3 = Moderate: Dull bright red erythema; moderate thickening; moderate scaling * 4 = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
Time frame: Week 12
Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 12
Percentage of participants achieving ≥50% reduction from baseline in PASI-50 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12
Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 12
Change From Baseline in PASI Score at Week 12
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Baseline, Week 12
Percent Change From Baseline in PASI Score at Week 12
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Baseline, Week 12
Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Percent Change From Baseline in the Percentage of BSA Affected at Week 12
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Pharmacokinetics (PK): Steady State Maximum Concentration of LY4100511 (Cmax,ss)
Steady State Maximum Concentration of LY4100511 (Cmax,ss) is reported.
Time frame: Day 1: Predose, 0.5, 1 hours postdose; Day 15: Predose, 0.5, 1, 4 hours postdose; Day 57: Predose, 0.5, 1, 4 hours postdose
Pharmacokinetics (PK): Steady State Trough Concentration (Ctrough,ss) of LY4100511
Ctrough,ss of LY4100511
Time frame: Predose at Day 8, 15, 29, 57 and 85
Number of Participants With TEAEs and SAEs Observed During the Study of LY4100511
The number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) observed during the study of LY4100511. A TEAE is defined as an AE that occurs during or after the first study drug administration and up to and including the follow-up visit. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: * Results in death * Is life-threatening (risk of death at the time of the event) * Requires inpatient hospitalization or prolongation of existing hospitalization (excluding elective admission for a stable pre-existing condition) * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Other medically important event that may jeopardize the participant or require intervention to prevent the above outcomes
Time frame: Baseline up to Week 12
| Milestone | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Started | 55 | 55 | 56 | 56 |
| Safety analysis population (received at least 1 dose of the study intervention) | 55 | 54 | 56 | 56 |
| Completed | 39 | 48 | 49 | 49 |
| Not completed | 16 | 7 | 7 | 7 |
| Withdrew: Adverse event | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 | 4 | 4 |
| Withdrew: Eligibility criteria not met | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 | 2 | 2 |
| Withdrew: Lack of efficacy | 5 | 1 | 1 | 0 |
| Withdrew: Request from subject | 0 | 1 | 0 | 0 |
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo) | 3.6 | 31.5 | 41.1 | 44.6 |
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 200mg vs 400mg vs 800mg) | 31.5 | 41.1 | 44.6 |
Percentage of participants achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 12. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): * 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur * 1 = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling * 2 = Mild: Pink to light red color; slight thickening; mainly fine scaling * 3 = Moderate: Dull bright red erythema; moderate thickening; moderate scaling * 4 = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 12 | 1.8 | 20.4 | 26.8 | 28.6 |
Percentage of participants achieving ≥50% reduction from baseline in PASI-50 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-50) at Week 12 | 20.0 | 51.9 | 69.6 | 66.1 |
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 | 3.6 | 31.5 | 41.1 | 44.6 |
Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12 | 1.8 | 11.1 | 17.9 | 25.0 |
Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12 | 0 | 5.6 | 7.1 | 10.7 |
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| score on a scale | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Change From Baseline in PASI Score at Week 12 | -5.24 (-7.14 to -3.35) | -10.01 (-11.89 to -8.14) | -12.75 (-14.58 to -10.93) | -11.36 (-13.18 to -9.54) |
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percent change | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percent Change From Baseline in PASI Score at Week 12 | -28.04 (-36.83 to -19.25) | -51.29 (-59.94 to -42.64) | -68.49 (-76.93 to -60.06) | -64.15 (-72.56 to -55.73) |
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
| percentage of BSA | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 12 | -2.82 (-5.85 to 0.20) | -10.20 (-13.19 to -7.21) | -11.21 (-14.13 to -8.30) | -11.71 (-14.62 to -8.81) |
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline BSA, prior biologic therapy (Yes/No), geographic region, and baseline BMI, baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
| Percent change | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Percent Change From Baseline in the Percentage of BSA Affected at Week 12 | -10.99 (-21.17 to -0.81) | -39.49 (-49.47 to -29.51) | -54.83 (-64.58 to -45.09) | -54.95 (-64.68 to -45.23) |
Steady State Maximum Concentration of LY4100511 (Cmax,ss) is reported.
| nanogram per millilitre (ng/mL) | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|
| Day 1 | 1640 ± 167 | 3330 ± 136 | 6550 ± 62.6 |
| Day 15 | 1950 ± 116 | 5370 ± 66.4 | 8060 ± 52.9 |
| Day 57 | 1860 ± 151 | 4890 ± 83.0 | 8670 ± 43.4 |
Ctrough,ss of LY4100511
| nanogram per millilitre (ng/mL) | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|
| Day 8 | 135 ± 95.6 | 306 ± 152 | 95.7 ± 111 |
| Day 15 | 111 ± 106 | 275 ± 219 | 83.0 ± 105 |
| Day 29 | 75.2 ± 166 | 290 ± 237 | 73.2 ± 128 |
| Day 57 | 108 ± 113 | 338 ± 99.4 | 97.1 ± 136 |
| Day 85 | 109 ± 163 | 382 ± 146 | 93.8 ± 153 |
The number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) observed during the study of LY4100511. A TEAE is defined as an AE that occurs during or after the first study drug administration and up to and including the follow-up visit. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: * Results in death * Is life-threatening (risk of death at the time of the event) * Requires inpatient hospitalization or prolongation of existing hospitalization (excluding elective admission for a stable pre-existing condition) * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Other medically important event that may jeopardize the participant or require intervention to prevent the above outcomes
| Participants | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| TEAE's | 28 | 23 | 30 | 29 |
| SAE's | 0 | 0 | 1 | 0 |
Collected over Baseline through End of follow-up (Up to 16 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo BID | 0/55 (0%) | 0/55 (0%) | 28/55 (50.9%) |
| LY4100511 200 mg BID | 0/54 (0%) | 0/54 (0%) | 23/54 (42.6%) |
| LY4100511 400 mg BID | 0/56 (0%) | 1/56 (1.8%) | 30/56 (53.6%) |
| LY4100511 800 mg QD | 0/56 (0%) | 0/56 (0%) | 29/56 (51.8%) |
| Event | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| Infective corneal ulcerInfections and infestations | 0/55 | 0/54 | 1/56 | 0/56 |
| Event | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/55 | 0/54 | 3/56 | 6/56 |
| Alanine aminotransferase increasedInvestigations | 2/55 | 1/54 | 5/56 | 2/56 |
| HeadacheNervous system disorders | 1/55 | 1/54 | 2/56 | 5/56 |
| VomitingGastrointestinal disorders | 0/55 | 3/54 | 0/56 | 1/56 |
| Upper respiratory tract infectionInfections and infestations | 1/55 | 3/54 | 3/56 | 1/56 |
| DiarrhoeaGastrointestinal disorders | 2/55 | 1/54 | 2/56 | 3/56 |
| FatigueGeneral disorders | 1/55 | 1/54 | 1/56 | 3/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/55 | 0/54 | 1/56 | 3/56 |
| NauseaGastrointestinal disorders | 1/55 | 2/54 | 0/56 | 2/56 |
| DizzinessNervous system disorders | 0/55 | 2/54 | 0/56 | 0/56 |
All participants who received at least 1 dose of the study intervention.
| Age, Continuous(years) | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 43.8 ± 11.39 | 46.8 ± 12.73 | 43.4 ± 12.05 | 43.6 ± 13.81 | 44.3 ± 12.52 |
| Sex: Female, Male(Participants) | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD | Total |
|---|---|---|---|---|---|
| Female | 16 | 22 | 19 | 23 | 80 |
| Male | 39 | 32 | 37 | 33 | 141 |
| Ethnicity (NIH/OMB)(Participants) | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 6 | 4 | 21 |
| Not Hispanic or Latino | 48 | 49 | 50 | 52 | 199 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo BID | LY4100511 200 mg BID | LY4100511 400 mg BID | LY4100511 800 mg QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 10 | 8 | 8 | 10 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 43 | 44 | 47 | 45 | 179 |
| More than one race | 2 | 1 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2024 to primary completion in Jul 2025, 8 months.
Results were first posted in Aug 2026, 1 year after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simepdekinra
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company →